Showing results (71-80 of 122) with videos related to

Sort By:
Pageof 13
Oncology|June 24, 2019
A Phase 1b/2 Study of the Bruton Tyrosine Kinase Inhibitor Ibrutinib and the PD-L1 Inhibitor Durvalumab in Patients with Pretreated Solid TumorsDavid Hong, Drew Rasco, Michael Veeder, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 19, 2008
Designing phase 0 cancer clinical trialsAnthony J Murgo, Shivaani Kummar, Larry Rubinstein, et al.
Leukemia & Lymphoma|September 23, 2023
Phase 1b dose-finding study of rituximab, lenalidomide, and ibrutinib (R2I) in patients with relapsed/refractory mantle cell lymphomaAndrew Ip, Alessandra Petrillo, Alexandra Della Pia, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 27, 2017
Discrimination of Germline <i>EGFR</i> T790M Mutations in Plasma Cell-Free DNA Allows Study of Prevalence Across 31,414 Cancer PatientsYuebi Hu, Ryan S Alden, Justin I Odegaard, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 31, 2023
Eganelisib, a First-in-Class PI3Kγ Inhibitor, in Patients with Advanced Solid Tumors: Results of the Phase 1/1b MARIO-1 TrialDavid S Hong, Michael Postow, Bartosz Chmielowski, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 13, 2011
A phase I study of PF-04929113 (SNX-5422), an orally bioavailable heat shock protein 90 inhibitor, in patients with refractory solid tumor malignancies and lymphomasArun Rajan, Ronan J Kelly, Jane B Trepel, et al.
Blood|February 27, 2019
Parsaclisib, a potent and highly selective PI3Kδ inhibitor, in patients with relapsed or refractory B-cell malignanciesAndres Forero-Torres, Radhakrishnan Ramchandren, Abdulraheem Yacoub, et al.
The Journal of Experimental Medicine|March 6, 2025
Estrogen influences class-switched memory B cell frequency only in humans with two X chromosomesHannah Peckham, Anna Radziszewska, Justyna Sikora, et al.
The Lancet. Oncology|February 25, 2018
Umbralisib, a novel PI3Kδ and casein kinase-1ε inhibitor, in relapsed or refractory chronic lymphocytic leukaemia and lymphoma: an open-label, phase 1, dose-escalation, first-in-human studyHoward A Burris, Ian W Flinn, Manish R Patel, et al.
Molecular Interventions|January 18, 2008
Phase 0 clinical trials in cancer drug development: from FDA guidance to clinical practiceRobert Kinders, Ralph E Parchment, Jay Ji, et al.
Pageof 13